Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Edap Tms Sa ADR (EDAP)

Edap Tms Sa ADR (EDAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,258
  • Shares Outstanding, K 37,104
  • Annual Sales, $ 65,400 K
  • Annual Income, $ -22,920 K
  • EBIT $ -22 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.33
  • Price/Sales 1.24
  • Price/Cash Flow N/A
  • Price/Book 1.71

Options Overview Details

View History
  • Implied Volatility 127.44% ( -122.95%)
  • Historical Volatility 63.51%
  • IV Percentile 80%
  • IV Rank 31.81%
  • IV High 378.65% on 11/27/24
  • IV Low 10.26% on 10/10/24
  • Put/Call Vol Ratio 0.53
  • Today's Volume 204
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 7,434
  • Open Int (30-Day) 7,198

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +2.34%
on 12/06/24
2.67 -17.90%
on 12/04/24
-0.26 (-10.61%)
since 11/20/24
3-Month
2.14 +2.34%
on 12/06/24
3.15 -30.48%
on 09/24/24
-0.86 (-28.20%)
since 09/20/24
52-Week
2.14 +2.34%
on 12/06/24
8.50 -74.24%
on 04/10/24
-2.81 (-56.20%)
since 12/20/23

Most Recent Stories

More News
EDAP TMS SA Announces Positive Results from Largest Clinical Study on Prostate Cancer Treatments, Highlighting Benefits of Focal One Robotic HIFU

The HIFI Study shows HIFU offers comparable efficacy and improved functional outcomes versus radical prostatectomy for localized prostate cancer.Quiver AI SummaryEDAP TMS SA announced the publication of...

EDAP : 2.19 (-0.23%)
EDAP TMS SA Reports Technical Feasibility of Histotripsy Lesion Generation Using Focal One® System

EDAP TMS reports successful ex vivo histotripsy lesion generation using Focal One® technology, promoting innovation in non-invasive therapies.Quiver AI SummaryEDAP TMS SA has announced a successful presentation...

EDAP : 2.19 (-0.23%)
EDAP TMS SA Presents Clinical Data Showing Robotic HIFU Reduces Post-Operative Complications Compared to Surgery for Deep Infiltrating Endometriosis

Robotic HIFU treatment for rectal endometriosis shows fewer complications and shorter hospital stays compared to traditional surgery.Quiver AI SummaryEDAP TMS SA announced positive clinical results regarding...

EDAP : 2.19 (-0.23%)
RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?

Rockwell Medical RMTI is scheduled to report third-quarter 2024 results on Nov. 11, before the opening bell.In the last reported quarter, the company’s adjusted earnings of 1 cent exceeded the Zacks...

RMTI : 2.08 (+1.46%)
IRIX : 1.6400 (-4.09%)
EDAP : 2.19 (-0.23%)
Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?

Good times continue for Rockwell Medical RMTI stock. Back-to-back big announcements over the recent months, like the company’s new launches for home hemodialysis, a multi-million-dollar distribution...

RMTI : 2.08 (+1.46%)
IRIX : 1.6400 (-4.09%)
EDAP : 2.19 (-0.23%)
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock

EDAP TMS EDAP has taken a significant step toward expanding its AI-assisted prostate cancer care through a strategic collaboration with AI healthcare company Avenda Health. This partnership is centered...

AXGN : 15.64 (+5.32%)
TMDX : 61.70 (+1.93%)
EDAP : 2.19 (-0.23%)
KIDS : 22.38 (-0.93%)
Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?

Rockwell Medical RMTI delivered an impressive performance through 2024, with its stock witnessing more than 108% year-to-date surge, outperforming the 15.5% rise of the industry and the benchmark’s 18.1%...

EDAP : 2.19 (-0.23%)
IRIX : 1.6400 (-4.09%)
RMTI : 2.08 (+1.46%)
EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Company to host conference call and webcast on Thursday, August 25th at 8:30 am EDT LYON, France, August 3, 2022 - EDAP TMS SA (Nasdaq: EDAP), the...

EDAP : 2.19 (-0.23%)
EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23

Proposed rule, if adopted for CY23, would increase Medicare Payment for a Focal One HIFU procedure completed on an outpatient basis at a hospital LYON,...

EDAP : 2.19 (-0.23%)
EDAP’s Focal One® HIFU to be Showcased at Two Major Robotics & Urology International Congresses

  LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its...

EDAP : 2.19 (-0.23%)

Business Summary

EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of...

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.32
1st Resistance Point 2.25
Last Price 2.19
1st Support Level 2.15
2nd Support Level 2.12
3rd Support Level 2.05

See More

52-Week High 8.50
Fibonacci 61.8% 6.07
Fibonacci 50% 5.32
Fibonacci 38.2% 4.57
Last Price 2.19
52-Week Low 2.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar